AMRN
Amarin·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
AMRN Profile
Amarin Corporation Plc
A biopharmaceutical company that develops and commercializes cardiovascular and lipid-focused therapeutics
Pharmaceutical
03/01/1989
04/02/1993
NASDAQ Stock Exchange
275
12-31
Depository Receipts (Ordinary Shares)
Iconic Offices, The Greenway, Block C Ardilaun Court, 112-114 St Stephens Green, Dublin 2, Ireland
--
Amarin Corporation Plc was incorporated in the United Kingdom on March 1, 1989. The Company is a pharmaceutical company focused on the commercialization and development of therapies that improve cardiovascular or cardiovascular health and reduce cardiovascular risk. The company's commercialized product, VASCEPA, was first approved by the U.S., or the U.S., the Food and Drug Administration, or the U.S. FDA, as a dietary supplement to reduce triglyceride or TG levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia, or marine indications.
